First investments of AMR Action Fund

The AMR Action Fund has announced its first investment to fulfill its aim to bring two to four new antibiotics to market. The fund will provide for research in Adaptive Phagte Therapeutics (APT) and Venatorx Pharmaceuticals.

“From inception, the AMR Action Fund has focused on identifying investments that will yield urgently needed treatments and catalyze long-term innovation to take on the growing threat of antimicrobial resistance (AMR), which now kills more people annually than HIV/AIDS or malaria,” said Bill Burns, Board Chair of the AMR Action Fund on their website. “Welcoming Adaptive Phage Therapeutics and Venatorx Pharmaceuticals as our first portfolio companies demonstrates that we are well on our way to fulfilling this important mission.”

Read the complete article: AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.